Academic journal

CB Scientific, Inc. Welcomes James Ott as Chief Technology Officer

Newly created position to lead technology innovation into the next stage of growth

ESCONDIDO, CA/ACCESSWIRE/May 3, 2022/ CB Scientific. Inc. (OTCQB: CBSC) (“CBSC” or the “Company”), a designer, manufacturer and marketer of non-invasive ambulatory cardiac monitoring products and services, today announces that effective immediately, James Ott has joined the Company’s management team as Chief Technology Officer. Mr. Ott brings deep industry experience to the company with seasoned experience in research and development, product design, material sourcing, production operations, logistics, quality systems and regulatory conformity.

“Jim has held a number of key leadership positions during his esteemed twenty-eight year career in the field of ambulatory ECG and clinical research trials, and we are delighted that he has agreed to help us heading into our next phase of business expansion. said Charles Martin, President and CEO of CB Scientific, Inc. “I have been fortunate to have worked with Jim on similar projects and, based on this exceptional experience, I am extremely confident that contributions to our future success will be both numerous and consecutive.”

After earning his Master of Science in Biomedical Engineering from Marquette University in 1991, Mr. Ott joined Biomedical System as a Product Manager where he coordinated the design, development and commercialization efforts of their platform lines. cardiac diagnostic software, including facilitating regulatory submissions and inspection. He eventually became President of the Cardiology Division of Biomedical Systems, where he managed all aspects of their Independent Diagnostic Testing Facility (IDTF), including international direct and distribution equipment sales, staffing IDTF Cardiology Laboratory, Technology, Sales and Marketing, Customer Service, Reimbursements, and Regulatory Activities. Mr. Ott was also an integral contributor to successful US patent submissions that resulted in granted approvals for three applications in 2004, 2005 and 2013, each of which lists him as one of the inventors.

“I am very pleased to join CB Scientific in this important new role of business leadership and look forward to working for an organization that is so uniquely positioned to deliver solutions that not only deliver breakthrough technology, but also enable clinicians to take better care. patients while achieving better operational, clinical and financial outcomes,” said Ott. “I am sincerely committed to expanding the Company’s opportunities, both domestically and internationally, to bring about real change in healthcare and increase value for our investors,” he added.

As new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants and markets informed public.

About CB Scientific, Inc.

CB Scientific, Inc., through its national and international subsidiaries, provides innovative products and services in the field of ambulatory noninvasive cardiac monitoring. Our FDA and CE cleared ECG devices, cloud-based interactive acquisition software, and smartphone apps for iOS and Android platforms provide enhanced compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.

Company details :

Phone: (888) 225-0870
Email: General Inquiries: [email protected]
Investor Requests: Robert Hesse – [email protected]
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube and Newsletter

This information disclosure may contain covered forward-looking statements within the meaning of the Private Securities Litigation Act of 1995. Such forward-looking statements relate to, among other things, plans and timing for the introduction or improvement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical facts and involve risks and uncertainties. Our expectations regarding future revenues depend on our ability to develop and deliver products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan”, “expect”, “believe” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in ubiquitous markets. This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from those projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and the approvals of regulatory authorities and shareholders for the planned actions.

THE SOURCE: CB Scientific, Inc.

See the source version on